Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact

Submit a comment

NF-κB drives epithelial-mesenchymal mechanisms of lung fibrosis in a translational lung cell model
Patrick Sieber, Anny Schäfer, Raphael Lieberherr, Silvia L. Caimi, Urs Lüthi, Jesper Ryge, Jan H. Bergmann, François Le Goff, Manuel Stritt, Peter Blattmann, Bérengère Renault, Patrick Rammelt, Bruno Sempere, Diego Freti, Rolf Studer, Eric S. White, Magdalena Birker-Robaczewska, Maxime Boucher, Oliver Nayler
Patrick Sieber, Anny Schäfer, Raphael Lieberherr, Silvia L. Caimi, Urs Lüthi, Jesper Ryge, Jan H. Bergmann, François Le Goff, Manuel Stritt, Peter Blattmann, Bérengère Renault, Patrick Rammelt, Bruno Sempere, Diego Freti, Rolf Studer, Eric S. White, Magdalena Birker-Robaczewska, Maxime Boucher, Oliver Nayler
View: Text | PDF
Research Article Cell biology Pulmonology

NF-κB drives epithelial-mesenchymal mechanisms of lung fibrosis in a translational lung cell model

  • Text
  • PDF
Abstract

In the progression phase of idiopathic pulmonary fibrosis (IPF), the normal alveolar structure of the lung is lost and replaced by remodeled fibrotic tissue and by bronchiolized cystic airspaces. Although these are characteristic features of IPF, knowledge of specific interactions between these pathological processes is limited. Here, the interaction of lung epithelial and lung mesenchymal cells was investigated in a coculture model of human primary airway epithelial cells (EC) and lung fibroblasts (FB). Single-cell RNA sequencing revealed that the starting EC population was heterogenous and enriched for cells with a basal cell signature. Furthermore, fractions of the initial EC and FB populations adopted distinct pro-fibrotic cell differentiation states upon cocultivation, resembling specific cell populations that were previously identified in lungs of patients with IPF. Transcriptomic analysis revealed active NF-κB signaling early in the cocultured EC and FB, and the identified NF-κB expression signatures were found in “HAS1 High FB” and “PLIN2+ FB” populations from IPF patient lungs. Pharmacological blockade of NF-κB signaling attenuated specific phenotypic changes of EC and prevented FB-mediated interleukin-6, interleukin-8, and CXC chemokine ligand 6 cytokine secretion, as well as collagen α-1(I) chain and α–smooth muscle actin accumulation. Thus, we identified NF-κB as a potential mediator, linking epithelial pathobiology with fibrogenesis.

Authors

Patrick Sieber, Anny Schäfer, Raphael Lieberherr, Silvia L. Caimi, Urs Lüthi, Jesper Ryge, Jan H. Bergmann, François Le Goff, Manuel Stritt, Peter Blattmann, Bérengère Renault, Patrick Rammelt, Bruno Sempere, Diego Freti, Rolf Studer, Eric S. White, Magdalena Birker-Robaczewska, Maxime Boucher, Oliver Nayler

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts